Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Simple item page
dc.catalogadorpva
dc.contributor.authorTesfai, Kaleb
dc.contributor.authorDíaz Piga, Luis Antonio
dc.contributor.authorArab, Juan Pablo
dc.contributor.authorArrese, Marco
dc.contributor.authorIdalsoaga, Francisco
dc.contributor.authorAyares, Gustavo
dc.contributor.authorAgrawal, Saaket
dc.contributor.authorBarreyro, Fernando Javier
dc.contributor.authorGadano, Adrian
dc.contributor.authorMarciano, Sebastián
dc.contributor.authorMartínez Morales, Jorge
dc.contributor.authorVillela‐Nogueira, Cristiane
dc.contributor.authorLeite, Nathalie
dc.contributor.authorSalles, Gil
dc.contributor.authorRegina Cardoso, Claudia
dc.contributor.authorAlves Couto, Claudia
dc.contributor.authorTheodoro, Rafael
dc.contributor.authorMonteiro. Mísia Joyner de Sousa Dias
dc.contributor.authorOliveira, Claudia P.
dc.contributor.authorPessoa, Mario G.
dc.contributor.authorAlvares‐da‐Silva, Mario Reis
dc.contributor.authorHuang, Daniel Q.
dc.contributor.authorMadamba, Egbert
dc.contributor.authorSingh, Seema
dc.contributor.authorLokanadham, Snigdha
dc.contributor.authorBettencourt, Ricki
dc.contributor.authorRichards, Lisa M.
dc.contributor.authorKhera, Amit V.
dc.contributor.authorLoomba, Rohit
dc.contributor.authorAjmera, Veeral
dc.date.accessioned2025-11-04T19:25:42Z
dc.date.available2025-11-04T19:25:42Z
dc.date.issued2025
dc.description.abstractIntroduction Previous studies have revealed conflicting results regarding liver fibrosis risk in lean metabolic dysfunction–associated steatotic liver disease (MASLD). We aimed to compare the risk of significant fibrosis in lean versus nonlean MASLD and identify fibrosis-associated factors in lean MASLD. Methods The study was a cross-sectional analysis of prospectively enrolled adults with MASLD. Individuals with lean MASLD were age- and sex-matched with nonlean MASLD. Fibrosis assessment included vibration-controlled transient elastography, magnetic resonance elastography and liver biopsy. A genetic risk score (GRS), summating the effect alleles of PNPLA3 and TM6SF2 minus the protective HSD17B13 genotype, was estimated to consider inherited genetic risk across BMI categories. Results were validated in an external Latin American cohort.ResultsThe mean ( SD) age of 312 included participants with MASLD was 58.3  11.6 years and 69.2% were female. 44 (14.1%) individuals were lean, 90 (28.9%) were overweight, 90 (28.9%) had class I obesity and 88 (28.1%) had class II or greater obesity. The prevalence of significant fibrosis was 27.3% in lean and 31.1% in nonlean (p = 0.653). Individuals with a high GRS had a higher prevalence of significant fibrosis compared to patients with low GRS (36.5% vs. 25.2%, p = 0.043) and the prevalence of significant fibrosis was similar in lean and nonlean patients with high GRS (31.3% vs. 37.1%, p = 0.645). The Latin American cohort exhibited similar results. Conclusions The prevalence of significant fibrosis and the effect of GRS were similar in lean and nonlean MASLD, highlighting that lean MASLD patients may have a comparable risk to overweight and obese MASLD.
dc.format.extent12 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1111/apt.70433
dc.identifier.eissn1365-2036
dc.identifier.issn0269-2813
dc.identifier.urihttps://doi.org/10.1111/apt.70433
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/106515
dc.information.autorucEscuela de Medicina; Díaz Piga, Luis Antonio; 0000-0002-8540-4930; 179253
dc.language.isoen
dc.nota.accesocontenido parcial
dc.publisherJohn Wiley & Sons Ltd.
dc.revistaAlimentary Pharmacology & Therapeutics
dc.rightsacceso restringido
dc.subjectFatty liver
dc.subjectGenetic risk score
dc.subjectMASLD
dc.subjectNITs
dc.subjectNonalcoholic fatty liver disease
dc.subjectNoninvasive tests
dc.subjectSignificant fibrosis
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleInherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
dc.typeartículo
sipa.codpersvinculados179253
sipa.trazabilidadORCID;2025-11-03
Files
Collections
Artículos de revistas